In light of these observations, we have evaluated the longer-term effects of interrupting the CD6-CD318 axis with UMCD6 on treatment of breast and prostate cancers in vivo and probed the mechanisms by which UMCD6 increased lymphocyte-mediated cytotoxicity against cancer cells. Here, CDCP1 is linked to prostate carcinoma.